Volume 36, Issue 1, Pages (October 2009)

Slides:



Advertisements
Similar presentations
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Advertisements

Volume 15, Issue 6, Pages (June 2009)
Volume 68, Issue 1, Pages e6 (October 2017)
Volume 34, Issue 6, Pages (June 2009)
Volume 19, Issue 2, Pages (July 2005)
Takashi Tanaka, Michelle A. Soriano, Michael J. Grusby  Immunity 
Volume 55, Issue 1, Pages (July 2014)
Volume 33, Issue 2, Pages (January 2009)
Histone Demethylase LSD2 Acts as an E3 Ubiquitin Ligase and Inhibits Cancer Cell Growth through Promoting Proteasomal Degradation of OGT  Yi Yang, Xiaotong.
Shitao Li, Lingyan Wang, Michael A. Berman, Ye Zhang, Martin E. Dorf 
Yu-Hsin Chiu, Jennifer Y. Lee, Lewis C. Cantley  Molecular Cell 
Volume 68, Issue 1, Pages e6 (October 2017)
Volume 36, Issue 2, Pages (October 2009)
Volume 22, Issue 5, Pages (May 2012)
Volume 23, Issue 1, Pages (July 2006)
NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression
Volume 130, Issue 3, Pages (August 2007)
Monica C. Rodrigo-Brenni, Erik Gutierrez, Ramanujan S. Hegde 
Volume 15, Issue 22, Pages (November 2005)
Eun-Joo Kim, Jeong-Hoon Kho, Moo-Rim Kang, Soo-Jong Um  Molecular Cell 
Yongli Bai, Chun Yang, Kathrin Hu, Chris Elly, Yun-Cai Liu 
Volume 63, Issue 6, Pages (September 2016)
IKKα Activation of NOTCH Links Tumorigenesis via FOXA2 Suppression
Volume 52, Issue 1, Pages 9-24 (October 2013)
Nithya Raman, Elisabeth Weir, Stefan Müller  Molecular Cell 
Volume 23, Issue 3, Pages (February 2013)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Ras Induces Mediator Complex Exchange on C/EBPβ
Volume 23, Issue 6, Pages (June 2013)
SUMO Promotes HDAC-Mediated Transcriptional Repression
Volume 39, Issue 4, Pages (August 2010)
Volume 43, Issue 5, Pages (September 2011)
Volume 55, Issue 4, Pages (August 2014)
Volume 29, Issue 4, Pages (February 2008)
Volume 18, Issue 5, Pages (January 2017)
SMRT Derepression by the IκB Kinase α
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 34, Issue 4, Pages (May 2009)
Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate- Cancer-Associated Mutants  Jian An, Chenji Wang, Yibin Deng, Long Yu,
TNF-Induced Activation of the Nox1 NADPH Oxidase and Its Role in the Induction of Necrotic Cell Death  You-Sun Kim, Michael J. Morgan, Swati Choksi, Zheng-gang.
Volume 39, Issue 3, Pages (August 2010)
Per Stehmeier, Stefan Muller  Molecular Cell 
Lysine 63 Polyubiquitination of the Nerve Growth Factor Receptor TrkA Directs Internalization and Signaling  Thangiah Geetha, Jianxiong Jiang, Marie W.
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
A Critical Role for Noncoding 5S rRNA in Regulating Mdmx Stability
Volume 35, Issue 6, Pages (September 2009)
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Volume 21, Issue 6, Pages (November 2017)
Volume 31, Issue 6, Pages (September 2008)
Mst1 Is an Interacting Protein that Mediates PHLPPs' Induced Apoptosis
Volume 43, Issue 4, Pages (October 2015)
Volume 30, Issue 6, Pages (June 2009)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 125, Issue 4, Pages (May 2006)
Hua Gao, Yue Sun, Yalan Wu, Bing Luan, Yaya Wang, Bin Qu, Gang Pei 
Volume 47, Issue 3, Pages (August 2012)
Volume 50, Issue 6, Pages (June 2013)
USP15 Negatively Regulates Nrf2 through Deubiquitination of Keap1
In Vitro Analysis of Huntingtin-Mediated Transcriptional Repression Reveals Multiple Transcription Factor Targets  Weiguo Zhai, Hyunkyung Jeong, Libin.
Volume 58, Issue 6, Pages (June 2015)
Volume 2, Issue 4, Pages (October 2002)
Volume 3, Issue 3, Pages (March 2013)
Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB
Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB  Wei-Chien Huang, Tsai-Kai Ju, Mien-Chie.
Volume 15, Issue 4, Pages (April 2009)
Volume 55, Issue 1, Pages (July 2014)
Suman Paul, Anuj K. Kashyap, Wei Jia, You-Wen He, Brian C. Schaefer 
A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program
Volume 41, Issue 4, Pages (February 2011)
Volume 31, Issue 5, Pages (September 2008)
Presentation transcript:

Volume 36, Issue 1, Pages 131-140 (October 2009) KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ  Dung-Fang Lee, Hsu-Ping Kuo, Mo Liu, Chao-Kai Chou, Weiya Xia, Yi Du, Jia Shen, Chun-Te Chen, Longfei Huo, Ming-Chuan Hsu, Chia-Wei Li, Qingqing Ding, Tsai-Lien Liao, Chien-Chen Lai, Ann-Chi Lin, Ya-Hui Chang, Shih-Feng Tsai, Long-Yuan Li, Mien-Chie Hung  Molecular Cell  Volume 36, Issue 1, Pages 131-140 (October 2009) DOI: 10.1016/j.molcel.2009.07.025 Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 1 KEAP1 Selectively Inhibits the NF-κB-Signaling Pathway (A) Ectopic of KEAP1 suppressed TNFα-mediated RELA nuclear translocation. Hs578T breast cancer cells were transfected with either RFP-KEAP1 or vector, serum-starved overnight, treated with 2 ng/ml TNFα for 30 min, stained with anti-RELA antibodies (green), and examined by confocal microscopy. The nucleus was stained with DAPI (blue). The arrow indicates KEAP1-expressed cells (red). (B) Depletion of endogenous KEAP1 by KEAP1 siRNA led to accumulation of nuclear RELA. (C) Knockdown of KEAP1 increased TNFα-induced NF-κB activation. The 5IκB-Luc reporter and TK-rLuc (internal control) were transfected with either KEAP1 siRNA or control siRNA into MDA-MB-435 cells. Then, 48 hr posttransfection, cells were serum starved overnight and treated with 2 ng/ml TNFα. After 8 hr of TNFα treatment, cells were recovered in 1% serum medium overnight and then lysed for luciferase assays. Error bars represent SD; n = 3. (D) Silencing KEAP1 by KEAP1 siRNA upregulated the expression of NF-κB-responsive genes in human breast cancer cells. A heat map depicts the relative expression of 12 NF-κB-dependent genes by qRT-PCR. A nonspecific siRNA was used as the control. (E and F) In vitro angiogenesis assays showed that the silencing of KEAP1 increases HUVEC tube formation and migration in comparison with the control. Depletion of IL-8 by antibodies to IL-8 (α-IL-8) suppressed knockdown of KEAP1-induced HUVEC migration and tube formation. Error bars represent SD; n = 3. (G and H) Depletion of KEAP1 following TNFα stimulation increased IL-8 mRNA and protein levels as determined by qRT-PCR and ELISA, respectively. Knockdown of NRF2 had no effects on KEAP1 depletion-induced IL-8 expression. Error bars represent SD; n = 3. Molecular Cell 2009 36, 131-140DOI: (10.1016/j.molcel.2009.07.025) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 2 KEAP1 Interacts with IKKβ via KEAP1 Kelch Domain (A) Depletion of endogenous KEAP1 by KEAP1 siRNA led to accumulation of IKKβ, but not of other components involved in NF-κB activation. (B) Exogenous interaction between KEAP1 and IKKβ. Lysates of HEK293T cells cotransfected with HA-tagged KEAP1 and Flag-tagged IKKβ. (C) Endogenous interaction between KEAP1 and IKKβ in both unstimulated and TNFα-stimulated MDA-MB-435 and HEK293 cells. (D) KEAP1 directly interacted with IKKβ. In vitro transcribed and translated [35S]-methionine-labeled KEAP1 proteins were incubated with recombinant His-tagged IKKβ proteins, pulled down by Ni2+ beads, separated by SDS-PAGE, and visualized by autoradiography. IVT, in vitro transcription and translation. (E) The effect of KEAP1 knockdown on TNFα-mediated IKKβ activation. (F) Interaction between the KEAP1 Kelch domain and IKKβ as examined by co-IP. Schematic shows five different domains of KEAP1, including an N-terminal region (amino acids 1–60), a BTB domain (amino acids 61–179), a BACK domain (amino acids 180–314), a Kelch domain (amino acids 315–598, six Kelch motifs), and a C-terminal domain (amino acids 599–624). (G) Mammalian two-hybrid assay revealed the direct interaction between KEAP1 Kelch domain and IKKβ. The indicated regions of KEAP1 fused to the GAL4 DNA-binding domain (DBD) were cotransfected VP16 activation domain (AD)-fused IKKβ (full-length), GAL4 luciferase reporter, and TK-rLuc reporter (internal control). Error bars represent SD; n = 3. Molecular Cell 2009 36, 131-140DOI: (10.1016/j.molcel.2009.07.025) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 3 KEAP1 Functions as a CUL3-Based E3 Ligase of IKKβ (A) KEAP1-dependent K48 ubiquitination of IKKβ in vivo. Flag-tagged IKKβ and HA-tagged KEAP1 were cotransfected with either wild-type or K48R mutant ubiquitin into HEK293T cells. After 24 hr posttransfection, cells were treated with MG132 for 6 hr. Flag-tagged IKKβ was immunoprecipitated, and then ubiquitination was analyzed by blotting with anti-ubiquitin antibody. (B) KEAP1 bridges the interaction between IKKβ and the CUL3-RBX1 complex. CUL3 immunoprecipitates were analyzed by immunoblot with the indicated antibodies. (C) In vitro ubiquitination of IKKβ by the KEAP1-CUL3-RBX1 complex. Flag-tagged IKKβ was incubated with KEAP1, CUL3, and RBX1 in the presence of E1, E2, His-Ubiquitin, and ATP as indicated. (D) Human IKKβ contains a KEAP1-binding (D/N)XE(T/S)GE motif (D, aspartic acid; N, asparagine; E, glutamic acid; T, threonine; S, serine; G, glycine; and X, any amino acid). (E) KEAP1 markedly decreased steady-state levels of wild-type, but not E36A and E39A mutant, IKKβ. GFP served as an internal control. (F and G) E36A and E39A mutant IKKβ markedly reduced their binding ability to KEAP1 and were resistant to KEAP1-mediated ubiquitination. (H) Mass spectrometry analysis revealed that IKKβ K555 is a polyubiquitination site. Flag-tagged IKKβ, HA-tagged KEAP1, and HA-tagged ubiquitin were cotransfected into HEK293T cells. After 1 day posttransfection, cells were treated with MG132 for 6 hr to prevent the degradation of polyubiquitinated IKKβ. Polyubiquitinated IKKβ were pulled down by using antibodies against HA tags and were analyzed by μ-LC/MS/MS mass spectrometry. Molecular Cell 2009 36, 131-140DOI: (10.1016/j.molcel.2009.07.025) Copyright © 2009 Elsevier Inc. Terms and Conditions

Figure 4 Negative Regulation of IKKβ by KEAP1-CUL3-RBX1 Ubiquitin Complex Is Altered in Human Cancers (A) Analysis of the CUL3, KEAP1, and RBX1 loci by 10 K SNP arrays in 42 breast cancer cell lines. Colograms represent SNP copy numbers. (Red) Allelic gain. (Green) Allelic loss. (B) SIGMA analysis of the CUL3, KEAP1, and RBX1 loci based on aCGH data. (Red) Areas of recurrent gain. (Green) Areas of recurrent loss. The maximum values of 1 and −1 represent gain and loss of that area in all samples, respectively. (C) A reverse clinical correlation existed between IKKβ, KEAP1, and CUL3 expression in 119 breast cancer specimens (p < 0.039). Hierarchical clustering was performed on the CLUSTER program and constructed using Treeview software to show a cohort of 119 breast cancer samples stained with IKKβ, KEAP1, and CUL3 expressions, and the heat map representation of the data is shown. Detailed information is presented in Table S3. (D) IKKβ expression levels were negatively associated with KEAP1 and CUL3 expression in 119 primary human breast cancer specimens. Shown are two representative specimens. (E) The Kaplan-Meier overall survival curves indicate that KEAP1 and CUL3 together are associated with an increase in overall survival in breast cancer patients. (F) In liver cancer, the KEAP1 Kelch domain mutants (S404X and D479G), but not the N domain mutant (G9R) or BACK domain mutant (H274L), have weaker binding abilities to IKKβ and consequently were unable to catalyze IKKβ ubiquitination. (G) Wild-type KEAP1 negatively downregulates NF-κB activity, and KEAP1 Kelch domain mutants (S404X and D479G) serve as dominant-negative forms to regulate NF-κB function. Endogenous KEAP1 was first knocked down by Accell KEAP1 siRNA, which targets the KEAP1 mRNA 3′UTR region. The KEAP1 knocked-down MDA-MB-435 cells were further transfected with wild-type and mutant KEAP1, and a panel of NF-κB-targeting gene expression was examined by qRT-PCR. Molecular Cell 2009 36, 131-140DOI: (10.1016/j.molcel.2009.07.025) Copyright © 2009 Elsevier Inc. Terms and Conditions